2020 Chemotherapy Foundation Symposium


Initial Therapy for Asymptomatic Follicular Lymphoma: Start With Watch and Wait or Rituximab

For patients with indolent follicular lymphoma, generally take a conservative approach to treatment unless the patient is symptomatic, advised John P. Leonard, MD, Executive Vice-Chair of Weill Depart...

Breast Cancer

Immunotherapy for Triple-Negative Breast Cancer: An Evolving Story

Immunotherapy with checkpoint inhibitors, established as a treatment of many solid tumors, may be finding a role in the treatment of breast cancer. The current state of the art regarding immunotherapy...

Prostate Cancer

Emerging Data on PARP Inhibition in Prostate Cancer

Prostate cancer has lagged behind other solid tumors with regard to molecularly targeted therapy and precision medicine, with no targeted therapies approved specifically in prostate cancer, but that h...


Front-Line Nonchemotherapy Regimens May Improve Long-Term Outcomes in CLL

An assortment of agents has been approved in the United States for the first-line treatment of chronic lymphocytic leukemia (CLL), and all of them are effective, explained Richard Furman, MD, of Weill...

Pancreatic Cancer

Options for Maintenance Therapy for Metastatic Pancreatic Cancer

Pancreatic cancer remains one of the most difficult-to-treat cancer types. Although there have been some advances in the past few years, the needle has not moved much on survival and prognosis. An imp...


Complexity of Designing Clinical Trials for Sarcoma: Shifting Focus to Constellation of Subtypes

Sarcoma has bedeviled researchers for many years because of its heterogeneity. Sarcoma encompasses more than 100 different subtypes, which makes it difficult to design studies to identify effective th...